title: The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies.
abstract: We carried out a prospective, randomized, double-blind, placebo-controlled study to investigate the capacity of aspirin to prevent pregnancy-induced hypertension and to alter prostaglandin metabolism. A total of 791 pregnant women with various risk factors for pre-eclamptic toxemia were screened with use of the rollover test (a comparison of blood pressure before and after the woman rolls from her left side to her back) during week 28 or 29 of gestation. Of 69 women with abnormal results (an increase in blood pressure during the rollover test), 65 entered the study and were treated with a daily dose of either aspirin (100 mg; 34 women) or placebo (31 women) during the third trimester of pregnancy. The number of women in whom pregnancy-induced hypertension developed was significantly lower among the aspirin-treated than among the placebo-treated women (4 [11.8 percent] vs. 11 [35.5 percent]; P = 0.024); the same was true for the incidence of preeclamptic toxemia (1 [2.9 percent] vs 7 [22.6 percent]; P = 0.019). The mean ratio of serum levels of thromboxane A2 to serum levels of prostacyclin metabolites after three weeks of treatment decreased by 34.7 percent in the aspirin-treated group but increased by 51.2 percent in the placebo-treated group. No serious maternal or neonatal side effects of treatment occurred in either group. We conclude that low daily doses of aspirin taken during the third trimester of pregnancy significantly reduce the incidence of pregnancy-induced hypertension and pre-eclamptic toxemia in women at high risk for these disorders, possibly through the correction of an imbalance between levels of thromboxane and prostacyclin.
authors.affiliation: Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Israel.
authors.forename: E
authors.initials: E
authors.lastname: Schiff
authors.forename: E
authors.initials: E
authors.lastname: Peleg
authors.forename: M
authors.initials: M
authors.lastname: Goldenberg
authors.forename: T
authors.initials: T
authors.lastname: Rosenthal
authors.forename: E
authors.initials: E
authors.lastname: Ruppin
authors.forename: M
authors.initials: M
authors.lastname: Tamarkin
authors.forename: G
authors.initials: G
authors.lastname: Barkai
authors.forename: G
authors.initials: G
authors.lastname: Ben-Baruch
authors.forename: I
authors.initials: I
authors.lastname: Yahal
authors.forename: J
authors.initials: J
authors.lastname: Blankstein
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D011464:Epoprostenol / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000517:prevention & control*; D011225:Pre-Eclampsia / Q000517:prevention & control; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control*; D011446:Prospective Studies; D011897:Random Allocation; D013928:Thromboxane A2 / Q000097:blood*
chemical_list: D013928:Thromboxane A2; D011464:Epoprostenol; D001241:Aspirin